Journals on Medical Research - BJSTR Journal

Abstract

#Pooled immunoglobulin (Ig) is a scarce and expensive resource, #hypertension is the leading cause of death worldwide (as of 2010) [1] as the new blood pressure guidelines in 2017 make note of [2], and there is something that can be done to address both. In this article, we summarize the salient developments in the treatment of hypertension as well as put forward the hypothesis that employing #thiazides in patients on chronic Ig #replacementtherapy may provide the dual benefit of treating blood pressure as well as increasing plasma concentration of immunoglobulins. Furthermore, there may be a side benefit to public health by increasing the supply of pooled immunoglobulin. According to the 2017 hypertension guidelines from the American Heart Association as well as a broad consensus of ten other organizations, hypertension is now defined as a #bloodpressure of greater than or equal to 130mm Hg systolic or 80mm Hg diastolic [1,2]. This threshold is lower than in JNC 8. As a result, the number of Americans who are now considered hypertensive is 46% while among elderly Americans, the figure is greater than 2/3. Furthermore, there are a series of well-known trials in internist circles called the Systolic Blood Pressure Intervention (SPRINT) trial which showed the benefits of even more intensive blood pressure control in certain demographics which constitute a very wide swathe of patients. SPRINT showed that among patients at high risk for cardiovascular events, “targeting a #systolic bloodpressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause” [3].

For more articles on BJSTR Journal please click on https://biomedres.us/

For more Medical Research Articles on BJSTR

https://biomedres.us/fulltexts/BJSTR.MS.ID.001549.php

Using Thiazides when #Hypertension is Coupled with Immunoglobulin Deficiency by Michael Saul Lundin in BJSTR